Latest news with #Healthcare
Forbes
5 hours ago
- Health
- Forbes
As Shared Decision-Making Ails, AI May Save This Human Interaction
Shared decision-making between doctors and patients may be 'the pinnacle of patient-centered care,' but three new medical journal articles suggest it's encountering more problems than peaks. Yet counterintuitively, it may be artificial intelligence that rescues this intimately human interaction. 'Shared decision-making is at a crossroads,' declares a Perspective in the Journal of General Internal Medicine, 'Saving Shared Decision-Making.' Unfortunately, its more-research-and-education recommendations for 'advancing the science of SDM implementation,' seem more crossing guard than crisis management. Even a cursory historical perspective shows that SDM is suffering from a failure to flourish. Back in 1982, a report by a presidential commission on ethics in medicine declared SDM 'the appropriate ideal for patient-professional relationships' and called on doctors 'to respect and enhance their patients' capacities for wise exercise of their autonomy.' Yet 43 years later, the Perspective authors – 18 members of the Agency for Healthcare Research and Quality Shared Decision-Making Learning Community – acknowledged that while some doctors respectfully ask patients, 'What do you think you would like to do, given these options?' many others still believe that, 'Let's do this option, sound OK?' is a shared decision process. That attitude reminded me of a tongue-in-cheek comment by comedian Stephen Colbert. 'See what we can accomplish when we work together by you doing what I say?' he told a 2015 Colbert Nation audience. 'It's called a partnership.' Cancer Communication Curtailed In cancer, where patient-doctor interactions have the highest stakes, shared decision-making was named one of the central components of quality care in a 1999 report, Ensuring Quality Cancer Care, by the Institute of Medicine (now the National Academy of Medicine). Nonetheless, a review of SDM among cancer patients in the journal Psycho-Oncology found that for physicians, 'making decisions and taking responsibility for the decisions remain an important part of the physicians' professional identity.' The fear of losing this identity, the authors wrote, 'tends to hinder the patient involvement and implementation of SDM.' Not surprisingly, cancer patients who want to speak up feel as if they won't be listened to or can't really refuse whatever their oncologist considers clinically 'optimal.' And, it turns out, oncologists are actually less open to SDM if a patient does speak up and resists the recommendations they feel are in the patient's best interest. Meanwhile, for those hoping Gen Z doctors will naturally be more sensitive, a JAMA Perspective, 'When Patients Arrive With Answers, brought discouraging news. When the topic of patients bringing in a treatment recommendation from ChatGPT came up among a group of medical students in the Seattle area, these Internet-native physicians of tomorrow bristled with an old-fashioned dismissiveness of the patient who's 'going to tell us what to order.' There's an implicit message that 'we still know best,' lamented Dr. Kumara Raja Sundar. AI Addresses Chronic Problem When you take a hard look at SDM use, misuse and non-use, it's clear this is a chronic problem, not an acute one. Good intentions collide with cultural norms going back to Hippocrates. The idea of patient self-determination, writes medical ethicist Dr. Jay Katz in The Silent World of Doctor and Patient, represents 'a radical break with medical practices, as transmitted from teacher to student during more than two thousand years of recorded medical history.' Perhaps equally important individual physicians are increasingly less likely to control their own time. In the 1980s, 80% of physicians worked in practices of ten or fewer doctors, according to the American Medical Association, and the overwhelming percentage of those were in private practice. In 2024, for the first time, private practice doctors were a minority, at just 42%, and about one in five doctors worked in practices of 50 or more. Paradoxically, AI may push shared decision-making onto what is now often an extremely time-pressured agenda precisely because the detailed, personalized level of information that it's able to force a reassessment of physician professional identity. Similarly, the scale, scope and depth of the AI revolution will also compel the group practice leaders, health system executives, private equity satraps and all others who now pull the strings on so many physicians to adapt to the democratization of medical knowledge. There may be no other choice. Already, individuals with breast, lung or prostate cancer can go to a well-funded start-up that will help them transfer their medical record into a platform that compares their treatment plan to the clinical practice guidelines of the National Comprehensive Cancer Network. Separately, a cancer survivor and entrepreneur has launched an online platform to make personalized agentic AI, a sophisticated search of the medical literature, available to every cancer patient. And real-world evidence in cancer care, now being marketed to clinicians and researchers, will inevitably be available directly to patients. Meanwhile, online venues like the PatientsUseAI Substack help guide those who wish to be full partners in their care how to use the new tools. The question no longer will be whether there is shared decision-making, but how it takes place. Sundar, a family physician, suggests 'relational humility,' with doctors 'seeing AI-informed visits as opportunities for deeper dialogue rather than threats to clinical authority.' He adds, 'If patients are arming themselves with information to be heard, our task as clinicians is to meet them with recognition, not resistance.'
Yahoo
2 days ago
- Business
- Yahoo
Australia Anti-Venom Market Analysis Report 2025-2033 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical
The Australia Anti Venom Market is poised for significant growth, reaching an estimated US$ 39.27 million by 2033 from US$ 22.18 million in 2024, at a CAGR of 6.55% from 2025 to 2033. This expansion is driven by increasing snake and scorpion bites, government initiatives, and industry advancements. Key market segments include Polyvalent and Monovalent Anti-Venoms, targeting snakes, scorpions, and spiders, distributed through clinics, hospitals, and surgical centers. Despite challenges like high production costs and geographic logistics, ongoing research and community engagement aim to enhance antivenom efficacy and accessibility. Major companies include CSL Limited and Pfizer Inc. Australian Anti-Venom Market Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "Australia Anti-Venom Market - Healthcare Demand & Forecast 2025-2033" report has been added to Anti Venom Market is expected to reach US$ 39.27 million by 2033 from US$ 22.18 million in 2024, with a CAGR of 6.55% from 2025 to 2033. Increasing rates of snake bites and scorpion stings, the introduction of beneficial government programs, and continuous industry advancements are some of the major factors propelling the market's expansion. The anti-venom business in Australia is essential to safeguarding the general public's health from the deadly and varied animals of the nation. The need for efficient anti-venom therapies is constantly high in areas with a high population of poisonous snakes and spiders. The industry functions through a network of organizations in charge of producing anti-venom, conducting research, and extracting venom. Together, these groups strive to guarantee a consistent flow of therapies that can save lives throughout the order to create anti-venom, venom from animals is usually collected and used to immunize host animals, such horses. The anti-venom is then made by harvesting and purifying antibodies. Although this approach hasn't altered much in decades, it still works well. The sector still confronts obstacles despite its shown success, such as high production costs and the requirement for anti-venoms that are appropriate for certain venom kinds. To overcome these obstacles and enhance results, research and innovation are still being conducted. Researchers are looking at universal anti-venoms that can cure various venom kinds as well as more effective manufacturing methods. Additionally, efforts are being made to make treatments more widely available, particularly in rural and isolated locations where bites are more common. In order to maintain national safety as the business develops, its capacity to address public health demands continues to be a top Factors Driving the Australia Anti Venom Market Growth High Incidence of Venomous BitesSome of the deadliest snakes and spiders in the world, such as the eastern brown snake, funnel-web spider, and inland taipan, may be found in Australia. A steady number of envenomation cases occur annually as a result of the widespread presence of these harmful species across the nation. The ongoing need for efficient anti-venom remedies is fueled by this public health concern. Particularly in rural and isolated areas where interactions are more frequent, hospitals and emergency services need to keep enough supplies on hand to react promptly to bites. Continued investment in the development and dissemination of anti-venoms is guaranteed by the necessity to treat both common and uncommon venom exposures. The need for dependable, quick-acting medical treatments like anti-venom therapy is growing as people become more aware of the dangers posed by local in Research and DevelopmentThe Australian anti-venom business is expanding due in large part to ongoing research and innovation. The goal of scientific research is to improve the accessibility, efficacy, and safety of therapies. The search for universal anti-venoms that can cure bites from many species is a significant area of development that might expedite emergency response and lower expenses. In order to boost productivity and lessen dependency on conventional animal-based vaccination, researchers are also trying to improve production techniques through the use of cutting-edge biotechnology. Collaboration among government organizations, pharmaceutical businesses, and academic institutions facilitates the creation of regionally customized solutions that are suited to Australia's distinct ecology. These developments guarantee that anti-venoms will continue to effectively combat changing venom characteristics and effectively and safely address public health Engagement and Public AwarenessIn Australia, the anti-venom business is greatly aided by community engagement. To properly catch and milk poisonous creatures, programs like wildlife parks' venom collecting campaigns need on volunteers and skilled specialists. In order to create medicines that can save lives, this gathered venom is essential. Public education initiatives also assist lower the number of fatalities and problems by increasing knowledge about the safety of snakes and spiders, first aid procedures, and the value of prompt medical attention. Raising awareness also promotes public and private funding for the study and manufacture of anti-venom. Australia guarantees a more proactive and robust approach to addressing the hazards posed by venomous animals by cultivating a culture of shared responsibility among scientists, healthcare professionals, and the general in the Australia Anti Venom Market High Production CostsThe high cost of manufacture is one of the main issues facing the Australian anti-venom business. The production of anti-venoms usually entails a time-consuming procedure that includes venom vaccination of animals (like horses) followed by the collection and purification of the antibodies. Manufacturing costs are increased by this labor-intensive and intricate process, which calls for specialized facilities and knowledgeable workers. Additionally, keeping a steady supply of venom from a variety of species raises the operational and logistical expenses. These costs can restrict access and frequently result in significant costs for healthcare providers, especially in rural or resource-poor locations where envenomation cases are more and Logistical ChallengesThe dissemination of anti-venoms is severely hampered by Australia's large and sometimes rural terrain. A large number of envenomation cases take place in isolated and rural areas with little access to healthcare services. It can be challenging to get temperature-sensitive anti-venoms to these locations in a timely and reliable manner, particularly in the event of severe weather or infrastructural failures. Coordinated logistics and significant money are needed to guarantee that remote clinics and hospitals have enough inventory. In these areas, inadequate access might cause treatment delays and worsen health outcomes. Improving response times and guaranteeing that all Australians, wherever they may be, have access to life-saving anti-venoms depend on resolving these logistical concerns. Company Analysis: Overview, Key Persons, Recent Developments, Revenue Analysis Bharat Serums and Vaccines Limited (BSV) Boehringer Ingelheim International GmbH Boston Scientific Corporation CSL Limited. Merck KGaA Pfizer Inc. Haffkine Bio-Pharmaceutical Corporation Limited Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $22.18 Million Forecasted Market Value (USD) by 2033 $39.27 Million Compound Annual Growth Rate 6.5% Regions Covered Australia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Australia Anti Venom Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Type6.2 By Animal Type6.3 By End Users7. Type7.1 Polyvalent Anti-Venom7.2 Monovalent Anti-Venom8. Animal Type8.1 Snake8.2 Scorpion8.3 Spider8.4 Others9. End Users9.1 Clinics9.2 Hospitals9.3 Ambulatory Surgical Centers9.4 Others10. Porter's Five Forces Analysis10.1 Bargaining Power of Buyers10.2 Bargaining Power of Suppliers10.3 Degree of Rivalry10.4 Threat of New Entrants10.5 Threat of Substitutes11. SWOT Analysis11.1 Strength11.2 Weakness11.3 Opportunity11.4 Threat12. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Australian Anti-Venom Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Air Liquide SA (AIQUF) (H1 2025) Earnings Call Highlights: Resilient Growth Amidst Challenges
Sales Growth: Sales grew by 2% on a comparable basis. Gas and Services OIR Margin Improvement: Improved by 130 basis points, excluding energy patrol effect. Efficiencies: Achieved EUR287 million, a 23% increase compared to H1 2024. Recurring ROCE: Improved to 11% despite increased investments. Investment Backlog: Reached a record high of EUR4.6 billion. Group Sales: Up 1.8% on a comparable basis for the first half. Order Intake: Reached EUR3,642 million, up 41% versus last year. Americas Sales Growth: Increased by 3% on a comparable basis. Healthcare Growth: Vigorous growth at 11.2% in the Americas. Operating Margin Improvement: Group operating margin improved by 100 basis points. Net Profit Growth: 8% excluding FX, with recurring net profit up 10.3%. Net Debt: EUR9.8 billion as of June 2025. Gearing: Stable at around 33.5% adjusted for dividend payment seasonality. Investment Opportunities: EUR4.1 billion as of June 2025. Investment Decisions: Recorded EUR2.3 billion for the first semester. Sales Contribution from Start-up and Ramp-up: Achieved EUR1.157 million in H1. Warning! GuruFocus has detected 2 Warning Signs with BOM:532388. Release Date: July 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Air Liquide SA (AIQUF) achieved a 2% sales growth on a comparable basis, demonstrating resilience in a challenging macroeconomic environment. The company reported a record gas and services operating income return (OIR) margin improvement of 130 basis points, excluding energy patrol effects. Air Liquide SA (AIQUF) delivered record efficiencies, reaching EUR287 million, a 23% increase compared to the first half of 2024. The company's recurring return on capital employed (ROCE) improved to 11%, despite increased investments. Air Liquide SA (AIQUF) has a solid investment backlog of EUR4.6 billion, securing future growth with projects already under construction. Negative Points The company faced challenges in the electronics sector, with a decrease in sales of equipment and installation compared to a record level last year. In Asia, merchant sales were generally soft, and pricing remained low due to neutral inflation. The inflationary environment remains a concern, particularly in China, where pricing is neutral. The company experienced a EUR190 million EBIT loss in the Non-gases & Services business, impacted by disposals in engineering. There is uncertainty in the regulatory environment for energy transition projects, which can lead to customer hesitation on major investment decisions. Q & A Highlights Q: Can you discuss Air Liquide's current leverage and plans for future M&A activities? A: Jerome Pelletan, CFO, stated that Air Liquide's gearing is stable at 33.5%, providing a strong balance sheet to support future investments. The company is focused on industrial projects and may consider acquisitions if they align with strategic growth opportunities. If investment opportunities are limited, they may return more cash to shareholders. Q: What are the plans for the remaining 40% capacity of the ELYgator project? A: Emilie Mouren Renouard, Group VP, explained that the ELYgator project will supply renewable hydrogen to TotalEnergies and other industries in the area. The project is connected to a pipeline network, offering flexibility to serve various customers, including mobility and transport markets. Q: Regarding the electronics investment in Dresden, will this fulfill anticipated needs, and how is it recorded in the results? A: Emilie Mouren Renouard, Group VP, confirmed that the EUR250 million investment in Dresden is the largest for electronics in Europe and enhances Air Liquide's position in the semiconductor market. EUR124 million of this investment is already included in the backlog. Q: How has the US legislative environment impacted Air Liquide's hydrogen projects? A: Adam Peters, CEO of North America, noted that the recent legislative changes, including the 45v tax credit, provide a favorable environment for low-carbon hydrogen projects. This clarity is expected to accelerate project developments, including potential collaborations with companies like Chevron. Q: What is the expected impact of European Union subsidies on the ELYgator project? A: Emilie Mouren Renouard, Group VP, mentioned that the ELYgator project benefits from European and Dutch government funding, covering 30% to 50% of the CapEx, which supports the project's financial viability. Q: Can you provide an update on Air Liquide's carbon capture projects for cement plants? A: Emilie Mouren Renouard, Group VP, stated that cement industry players are actively pursuing decarbonization, with projects depending on regulatory frameworks and funding. Air Liquide is working closely with these players to develop viable carbon capture solutions. Q: How is Air Liquide's comparable growth progressing, and what is the outlook for the second half of the year? A: CEO Francois Jackow expects similar top-line momentum for the rest of the year, with resilient sales across geographies and business lines. While there are positive signs in electronics and US policy effects, the company remains cautious due to ongoing uncertainties. Q: Will Air Liquide revisit its margin targets given the current performance? A: CEO Francois Jackow indicated that while it's early to update guidance, the company is confident in achieving its 200 basis points margin improvement target for 2025 and 2026, driven by ongoing transformation initiatives. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
3 days ago
- Business
- Yahoo
Medical Gas Market Forecast and Company Analysis Report 2025-2033 Featuring Air Liquide, Linde, Atlas Copco, Inox-Air, Taiyo Nippon Sanso, Matheson Tri-Gas, Horiba, Sol
The Global Medical Gas Market is projected to grow from US$ 14.41 billion in 2024 to US$ 28.61 billion by 2033, with a CAGR of 7.92%. Key drivers include a shift toward home healthcare and telemedicine, rising chronic diseases, and advancements in medical technology. The Asia-Pacific region is expected to see the highest growth due to expanding healthcare sectors. The market faces challenges like stringent regulations and supply chain disruptions. High demand for portable solutions, growing telemedicine, and numerous chronic conditions are shaping the industry. Key players include Air Liquide, Linde PLC, and Atlas Copco Group. Medical Gas Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Medical Gas Market Share Analysis and Size - Growth Trends and Forecast Report 2025-2033" report has been added to Global Medical Gas Market is expected to reach US$ 28.61 billion by 2033 from US$ 14.41 billion in 2024, with a CAGR of 7.92% from 2025 to 2033. Some of the key reasons driving the market are the growing tendency toward home healthcare and telemedicine, the prevalence of chronic illnesses including respiratory and cardiovascular diseases (CVDs), and many developments in medical technology. The aging population, rising rates of chronic respiratory conditions, and improvements in healthcare infrastructure are all contributing to the substantial expansion of the worldwide medical gas market. Medical gases, such as carbon dioxide, nitrous oxide, and oxygen, are necessary for a number of therapeutic and diagnostic uses in ambulatory surgery centers, home healthcare settings, and hospitals. The need for portable medical gas solutions, such oxygen concentrators, has increased due to the growing demand for home healthcare services. Due to growing healthcare sectors and government expenditures in medical infrastructure, the Asia-Pacific region is expected to develop at the highest rate, while North America already has a significant market share. The availability and distribution of medical gases may be impacted by supply chain interruptions and strict regulatory restrictions, which provide difficulties for the need for medicinal gases is also being fueled by the increasing incidence of asthma. The Australian Institute of Health and Welfare (AIHW) estimates that in 2023, asthma accounted for 35% of the entire burden related to all respiratory disorders and 2.5% of the overall illness burden. Nitrous oxide, carbon dioxide, nitrogen, oxygen, and medical air are some of the most often utilized medical gases in of the leading companies, Air Liquide Healthcare, provides medicinal gases to 20,000 hospitals and new healthcare facilities, and assists over 2 million people in managing chronic illnesses. Medical gases including heliox, oxygen, and lung gas mixes are widely employed in the diagnosis and treatment of certain respiratory the need for portable medical gases, such as oxygen concentrators, is rising as more people choose home-based healthcare. In order to ensure that chronic patients receive the oxygen therapy they require at home, this change places an emphasis on convenience and continuity of care. Home healthcare has become increasingly popular in recent years and is predicted to continue to grow. Many medical illnesses may now be successfully treated at home, including those that require ventilator assistance, mixed gas therapies, and long-term oxygen therapy. Additionally, it is anticipated that rising home healthcare reimbursement would support market expansion throughout the projection period. The Firesafe Cannula Valve, for example, was formally covered by Iowa Medicaid in November 2023 and was given the HCPCS number E0700 for reimbursement. In the event that the oxygen tubing downstream burns, this novel mechanism functions as a thermal fuse and instantly stops the oxygen supply. Thermal fuses must be installed in all home oxygen systems in the United Kingdom. Interestingly, the US has a 20-fold greater risk of death from oxygen-related flames than England, where installing firebreaks has been required since Drivers for the Medical Gas Market Numerous Medical Technology AdvancementsLaparoscopy and endoscopy are examples of minimally invasive (MI) surgical techniques that have been made possible by technological breakthroughs. Surgeons can execute treatments with fewer incisions, quicker patient recovery, and less tissue stress when medical gases like carbon dioxide are utilized to provide a clean operating field. Furthermore, more specialized and individualized treatment for respiratory problems is now possible because to developments in respiratory therapy equipment. The World Health Organization reports that asthma and other chronic respiratory diseases (CRDs) are on the rise worldwide, with 3.2 million deaths from COPD and 262 million cases of asthma in 2019. Advanced oxygen treatment equipment, such as portable oxygen delivery systems and oxygen concentrators, are used to supply medical gases like oxygen. Additionally, a number of developments in dermatology and cryosurgery have increased the use of medicinal gases, such as liquid nitrogen, to freeze and remove sick or aberrant tissue. The market is being driven by the regulated and focused treatment that cryotherapy equipment provides, which minimizes harm to nearby healthy Preference for Telemedicine and Home HealthcareMedical gases, such as oxygen, are frequently given to patients in their homes as part of home healthcare. To control their symptoms and enhance their quality of life, patients with long-term respiratory diseases like COPD need oxygen treatment. Medical oxygen gases are in greater demand as a result of the shift toward home healthcare, which enables patients to obtain oxygen therapy without the need for extended hospital stays. Furthermore, nebulization, pain relief, and respiratory therapies are only a few of the uses for medical gases that go beyond oxygen therapy. As a result of this trend, fewer extended hospital stays are required, which raises the requirement for medical as cardiovascular disorders are thought to cause 17.9 million deaths worldwide each year, medicinal gases - such as oxygen - are essential for treating associated ailments, which raises the need for at-home therapies. The need for medical gases is further increased by the growth of telemedicine and home healthcare, which enables patients to receive a greater variety of medical gas treatments in the convenience of their own Rates of Chronic Conditions, Including Heart and Respiratory ConditionsMedical gases like oxygen are necessary for respiratory support because to the rising prevalence of respiratory conditions such asthma, interstitial lung disorders, and chronic obstructive pulmonary disease (COPD). Chronic respiratory disorders (CRDs), such as asthma, interstitial lung diseases, and chronic obstructive pulmonary disease (COPD), are on the rise, according to the World Health Organization (WHO). According to the Global Asthma Report, asthma affects an estimated 262 million people globally, and COPD alone was responsible for almost 3.2 million deaths in treatment is necessary for patients who have trouble breathing in order to keep their blood oxygen levels sufficient and to relieve their symptoms. Furthermore, medicinal gases are frequently needed for diagnostic and therapeutic purposes in cardiovascular illnesses, such as heart failure, coronary artery disease, and hypertension. In order to ensure patient comfort and stability during cardiovascular procedures, nitrous oxide is used as an anesthetic agent. Additionally, medicinal gases are essential for palliative care for individuals with chronic illnesses that have in the Medical Gas Market Stringent Regulatory ComplianceBecause medical gases are essential to patient care and safety, the market is subject to strict regulatory compliance. To guarantee that medical gases fulfill therapeutic needs, regulatory agencies impose stringent criteria for purity, labeling, packing, and transportation. Operational complexity can be further increased by the constant monitoring, certification procedures, and thorough paperwork that are frequently required to comply with these rules. To maintain compliance, manufacturers must spend more on qualified staff and sophisticated quality control systems, which raises prices. Furthermore, managing disparate regional restrictions might make international distribution plans more difficult. Although these regulations guarantee patient safety and product dependability, they also place a financial and logistical strain on manufacturers, particularly newly established smaller Production and Storage CostsComplex infrastructure and procedures are needed to produce and store medicinal gases, which raises supply chain costs. To guarantee purity and safety, the gases need to be produced under exacting circumstances, which calls for cutting-edge technology and strict adherence to regulations. Energy-intensive systems are needed for compression and liquefaction, and storage facilities need to be built to withstand temperature changes, pollution, and leakage. Specialized, frequently temperature-controlled containers that adhere to stringent rules are also necessary for the transportation of these gases. Long-term costs are further increased by continuing storage system monitoring and maintenance. These elements work together to make medical gases far more expensive to produce, handle, and distribute than many other medical supplies, which puts a strain on both healthcare providers and suppliers. Key Players Analyzed: Overview, Key Persons, Recent Development & Strategies, Revenue Analysis Air Liquide Linde Plc Atlas Copco Group Inox-Air Products Inc. Taiyo Nippon Sanso Corporation Matheson Tri-Gas, Inc. Horiba Group Sol India Private Limited Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $14.41 Billion Forecasted Market Value (USD) by 2033 $28.61 Billion Compound Annual Growth Rate 7.9% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Medical Gas Market5.1 Historical Market Trends5.2 Market Forecast6. Medical Gas Market Share Analysis6.1 By Product6.2 By Application6.3 By End Use6.4 By Countries7. Product7.1 Pure Gases7.2 Gas Mixtures8. Application8.1 Therapeutics8.2 Diagnostics8.3 Others9. End Use9.1 Hospitals9.2 Pharmaceutical & Biotechnology Companies9.3 Ambulatory Surgical Centers9.4 Diagnostic & Research Laboratories9.5 Academic & Research Institutes9.6 Home Healthcare10. Countries10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia-Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 South Korea10.3.5 Thailand10.3.6 Malaysia10.3.7 Indonesia10.3.8 Australia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 Saudi Arabia10.5.2 UAE10.5.3 South Africa11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Medical Gas Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Health Line
3 days ago
- Health
- Health Line
A Guide to Gait Training Exercises for Older Adults
Gait training is a form of physical therapy that helps improve your walking ability. It may involve exercises for balance, strength, and coordination. This may be helpful for older adults who have recently experienced a fall. A healthcare professional may recommend gait training if you have recently experienced an illness or injury that affects your ability to walk. This type of physical therapy can be useful in helping you regain independence in walking, even if you may still require a walking aid. Gait training can help: strengthen muscles and joints improve balance and posture develop muscle memory build endurance retrain your legs for repetitive motion reduce your risk of falls increase mobility There are various types of exercises that may help improve your gait. Important considerations Consult a physical therapist or healthcare professional before beginning any new exercises, especially if you have underlying health conditions or mobility issues. Start slowly and gradually increase the duration and intensity of each exercise as your strength and balance improve. Listen to your body and stop an exercise if you feel pain. Ensure you are doing exercises in a safe environment with proper support and supervision if needed. Balance exercises Balance exercises can help reduce your risk of falls and improve your mobility. You may want to do these exercises near a wall or sturdy chair for extra help with balance. Heel-to-toe walk Stand upright. Place your right heel on the floor directly in front of your left toe. Repeat with the other side, placing your left heel in front of your right toe. Keep looking forward at all times and place your fingers against a wall if you need extra stability. Aim for at least 5 steps. As you feel stronger and more balanced, move away from the wall. One-leg stand Stand facing a wall with your arms outstretched. Touch your fingertips to the wall. Lift your left leg, keeping your hips level. Keep a slight bend in the opposite knee. Hold the lift for 5 to 10 seconds. Gently place your foot back on the floor. Repeat with the other leg. Try to perform 3 lifts on each side. Simple grapevine This exercise involves walking sideways by crossing one foot over the other. Rest your fingers against a wall while you do this exercise if you need extra stability. Stand upright. Cross your right foot over your left. Bring your left to join your right. Aim for 5 cross-steps on each side. »Learn more: Balance exercises for older adults Strength exercises Repetition vs. set A repetition is one complete movement of an exercise, such as lifting a weight or doing a sit-up. You should aim for 8 to 12 repetitions, which counts as one set. The Centers for Disease Control and Prevention (CDC) recommends that older adults get 150 minutes of moderate intensity activity each week. It also recommends that older adults add at least 2 days of strength training. Strength training exercises can help you to strengthen your muscles and joints. They can also help improve your balance, reducing your risk of falls and improving mobility. Heel raises Stand up straight with your feet slightly apart, toes facing forward, and your weight evenly distributed. Hold onto a firm and stable surface like a kitchen counter or stable chair for support. Slowly lift both your heels off the floor while keeping your back and knees straight. Slowly lower your heels back to the floor. Repeat this exercise 8 to 15 times. If needed, you can do this exercise sitting down: Sit in a sturdy chair with your feet flat on the floor. Lift your heels off the floor by raising and lowering your knees. Sit to stand Sit upright in a sturdy chair, leaning slightly forward so you are not resting against the back. Make sure your feet are shoulder-width apart and your knees are bent about 90 degrees. Stand up slowly and then gradually sit back down. Repeat this exercise 8 to 15 times. If you need a bit of extra support, you can place your hands on your thighs or on armrests if your chair has them. As you begin to feel stronger, you can do this exercise without the use of your hands. Side leg lifts Stand upright with your feet together and your toes facing forward. Hold onto a firm surface like a countertop or sturdy chair for extra support, or put your hands on your hips if it makes you feel more balanced. Lift one leg off the floor and out to the side, no more than 30 degrees. Keep your leg straight. Slowly bring your leg back to the starting position. Repeat this exercise 8 to 15 times on each leg. Coordination and walking exercises Coordination exercises can help improve balance and strength. Some of them can also help improve cardiovascular health. Marching in place Stand tall or sit upright in a chair. Lift your feet alternately in a marching motion. Be sure to keep your back straight throughout. Try not to stomp your feet but make sure your foot goes fully back on the ground each time Try to march in place for 20 to 30 seconds. Sideways walking Stand upright with your feet together and knees slightly bent. In a slow and controlled motion, step sideways with one foot. Move your other foot to join it. Avoid dropping your hips as you step. Try to perform 10 steps each way. Stepping over objects Place a few small to medium soft objects on the floor a short distance apart, or have someone help you place objects on the floor Make sure the objects are placed at a distance where it feels natural to step over them with each foot Step over each object several times You can also practice side-stepping over the objects by lifting your foot and stepping sideways over each one a few times.
